patient

PAUL J. SHAMI, MD

Institution
Huntsman Cancer Institute
Physician Status
accepting new patients
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
About
Languages Spoken: English, French, Arabic Dr. Paul Shami is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies at the University of Utah and is a Member and Clinical Investigator at the University’s Huntsman Cancer Institute (HCI). Dr. Shami also holds an Adjunct appointment as a Professor of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. He is Board Certified in Hematology and Medical Oncology. He started at the University of Utah in 1997. Dr. Shami oversees leukemia clinical trials at Huntsman Cancer Institute. His research also includes

Evaluation of the Quality of Life and Treatment Experiences of Patients with Paroxysmal Nocturnal Hemoglobinuria

The purpose of the study is to learn what it is like to have PNH and being treated with for PNH. Individuals who participate in the study will complete an online survey about what it is like to live with PNH. The survey will take about 45 minutes. Participants may also be asked to take part in a one-hour interview by telephone or computer. The interviewer will ask questions about what it is like to have, and be treated for, PNH. No medical treatment of any kind will be given as part of this study.

Hello!

What is the IPSS-M for MDS?

Thumbnail for video Watch Now

Topic(s)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Gail J. Roboz, M.D.
In this webinar, Dr. Gail Roboz discusses the Molecular International Prognostic Scoring System (IPSS-M) which is a newly developed risk stratification model for myelodysplastic syndromes (MDS) that expands on the original IPSS-R by including data on somatic oncogenic mutations…
Subscribe to patient

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.